FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4375846951> ?p ?o ?g. }

• W4375846951 endingPage "615.e8" @default.
• W4375846951 startingPage "615.e1" @default.
• W4375846951 abstract "Introduction Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases is not fully established. Patients and Methods Ancillary analysis from the GETUG 12 phase 3 trial. Patients with non-metastatic high-risk prostate cancer by bone and computerized tomography (CT) scan were randomly assigned to receive androgen deprivation therapy (ADT) and docetaxel plus estramustine or ADT alone. Relapse-free survival (RFS), clinical RFS, metastases-free survival (MFS), overall survival (OS), and prostate cancer-specific survival (PCSS) were estimated using the Kaplan–Meier method for different levels of PSA (50 ng/mL, 75 ng/mL, and 100 ng/mL). The relationship between PSA and outcomes was studied using residual-based approaches and spline functions. Results The median follow-up was 12 years (range: 0-15.3). Baseline PSA (<50 ng/mL, n = 328; ≥50ng/mL, n = 85) was associated with improved RFS (P = .0005), cRFS (P = .0024), and MFS (P = .0068). The 12-year RFS rate was 46.33% (CI 40.59-51.86), 33.59% (CI 22.55-44.97), and 11.76% (1.96-31.20) in men with PSA values <50 ng/mL (n = 328), 50-100 ng/mL (n = 68), and ≥100 ng/mL (n = 17), respectively. Exploratory analyses revealed no deviation from the linear relationship assumption between PSA and the log hazard of events. Conclusions Men with apparently localized prostate cancer and a high baseline PSA value have a reasonable chance of being long-term disease-free when treated with curative intent combining systemic and local therapy." @default.
• W4375846951 created "2023-05-10" @default.
• W4375846951 creator A5001456598 @default.
• W4375846951 creator A5002406245 @default.
• W4375846951 creator A5007779528 @default.
• W4375846951 creator A5011506675 @default.
• W4375846951 creator A5013759812 @default.
• W4375846951 creator A5016485718 @default.
• W4375846951 creator A5019500272 @default.
• W4375846951 creator A5021549650 @default.
• W4375846951 creator A5024331920 @default.
• W4375846951 creator A5026180389 @default.
• W4375846951 creator A5026462289 @default.
• W4375846951 creator A5031054777 @default.
• W4375846951 creator A5032656430 @default.
• W4375846951 creator A5032686530 @default.
• W4375846951 creator A5033220136 @default.
• W4375846951 creator A5034922000 @default.
• W4375846951 creator A5035139653 @default.
• W4375846951 creator A5035784239 @default.
• W4375846951 creator A5040479101 @default.
• W4375846951 creator A5041283530 @default.
• W4375846951 creator A5043616693 @default.
• W4375846951 creator A5046909112 @default.
• W4375846951 creator A5048846499 @default.
• W4375846951 creator A5049271819 @default.
• W4375846951 creator A5049406196 @default.
• W4375846951 creator A5049633907 @default.
• W4375846951 creator A5057183350 @default.
• W4375846951 creator A5058986182 @default.
• W4375846951 creator A5059690857 @default.
• W4375846951 creator A5065732872 @default.
• W4375846951 creator A5067036952 @default.
• W4375846951 creator A5081051779 @default.
• W4375846951 creator A5082334341 @default.
• W4375846951 creator A5083891313 @default.
• W4375846951 date "2023-10-01" @default.
• W4375846951 modified "2023-10-14" @default.
• W4375846951 title "Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial" @default.
• W4375846951 cites W1489963450 @default.
• W4375846951 cites W1570622790 @default.
• W4375846951 cites W1787922333 @default.
• W4375846951 cites W2016006304 @default.
• W4375846951 cites W2018183502 @default.
• W4375846951 cites W2018407860 @default.
• W4375846951 cites W2020013971 @default.
• W4375846951 cites W2034948055 @default.
• W4375846951 cites W2050949576 @default.
• W4375846951 cites W2064799866 @default.
• W4375846951 cites W2112080888 @default.
• W4375846951 cites W2114235736 @default.
• W4375846951 cites W2117792530 @default.
• W4375846951 cites W2142629844 @default.
• W4375846951 cites W2142635246 @default.
• W4375846951 cites W2159493972 @default.
• W4375846951 cites W2160217483 @default.
• W4375846951 cites W2172227211 @default.
• W4375846951 cites W2281000077 @default.
• W4375846951 cites W2311474528 @default.
• W4375846951 cites W2511949746 @default.
• W4375846951 cites W2568568733 @default.
• W4375846951 cites W2756428015 @default.
• W4375846951 cites W2897236707 @default.
• W4375846951 cites W2898289654 @default.
• W4375846951 cites W2902543395 @default.
• W4375846951 cites W2923649249 @default.
• W4375846951 cites W3191534679 @default.
• W4375846951 cites W4200457203 @default.
• W4375846951 cites W4294715705 @default.
• W4375846951 cites W2168368289 @default.
• W4375846951 doi "https://doi.org/10.1016/j.clgc.2023.05.003" @default.
• W4375846951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37263910" @default.
• W4375846951 hasPublicationYear "2023" @default.
• W4375846951 type Work @default.
• W4375846951 citedByCount "0" @default.
• W4375846951 crossrefType "journal-article" @default.
• W4375846951 hasAuthorship W4375846951A5001456598 @default.
• W4375846951 hasAuthorship W4375846951A5002406245 @default.
• W4375846951 hasAuthorship W4375846951A5007779528 @default.
• W4375846951 hasAuthorship W4375846951A5011506675 @default.
• W4375846951 hasAuthorship W4375846951A5013759812 @default.
• W4375846951 hasAuthorship W4375846951A5016485718 @default.
• W4375846951 hasAuthorship W4375846951A5019500272 @default.
• W4375846951 hasAuthorship W4375846951A5021549650 @default.
• W4375846951 hasAuthorship W4375846951A5024331920 @default.
• W4375846951 hasAuthorship W4375846951A5026180389 @default.
• W4375846951 hasAuthorship W4375846951A5026462289 @default.
• W4375846951 hasAuthorship W4375846951A5031054777 @default.
• W4375846951 hasAuthorship W4375846951A5032656430 @default.
• W4375846951 hasAuthorship W4375846951A5032686530 @default.
• W4375846951 hasAuthorship W4375846951A5033220136 @default.
• W4375846951 hasAuthorship W4375846951A5034922000 @default.
• W4375846951 hasAuthorship W4375846951A5035139653 @default.
• W4375846951 hasAuthorship W4375846951A5035784239 @default.
• W4375846951 hasAuthorship W4375846951A5040479101 @default.
• W4375846951 hasAuthorship W4375846951A5041283530 @default.
• W4375846951 hasAuthorship W4375846951A5043616693 @default.
• W4375846951 hasAuthorship W4375846951A5046909112 @default.

• next